CytomX Therapeutics, Inc. (CTMX) vs Fulgent Genetics, Inc. (FLGT)

A side-by-side comparison of CytomX Therapeutics, Inc. and Fulgent Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CTMX vs FLGT

growth of $100 · dividends reinvested · last 10y
CTMX -83.1% (-16.3%/yr)FLGT +130.1% (+8.7%/yr)FLGT compounded faster over this window
Log scale — wide-divergence pair
1101001k10kStart $10020182020202220242026$17$230
CTMX FLGT

CTMX vs FLGT: by the numbers

  • •FLGT is the larger company ($588M vs $563M market cap).
  • •Both run net losses; FLGT's is the smaller (-26.05% vs -435.21% net margin).
  • •CTMX grew revenue faster over the past five years (2.18% vs -18.66% CAGR).

Metrics side by side

Valuation

MetricCTMXFLGT
P/S ratio30.751.81
P/B ratio1.860.59

Profitability

MetricCTMXFLGT
Gross margin98.63%35.58%
Operating margin-29.35%-28.23%
Net margin-435.21%-26.05%
ROE-26.37%-8.42%
ROIC-25.42%-11.80%

Growth (annualized)

MetricCTMXFLGT
Revenue CAGR (5Y)2.18%-18.66%
Total return CAGR (5Y)-12.01%-22.38%

Frequently asked

Which has grown faster, CTMX or FLGT?
Over the past five years, CTMX grew revenue faster — CTMX at a 2.18% CAGR versus FLGT at -18.66%.
How have CTMX and FLGT total returns compared?
Over the past 10 years, CTMX delivered -16.62% and FLGT delivered 8.90% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.